home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9409d.zip
/
M9490502.TXT
< prev
next >
Wrap
Text File
|
1994-09-24
|
2KB
|
32 lines
Document 0502
DOCN M9490502
TI Pharmacodynamic relationship of pharmacokinetic parameters of
maintenance doses of foscarnet and clinical outcome of cytomegalovirus
retinitis.
DT 9411
AU Jacobson MA; Polsky B; Causey D; Davis R; Tong W; O'Donnell JJ;
Kuppermann BD; Heinemann MH; Feinberg J; Lizak P; et al; Department of
Medicine, University of California, San Francisco.
SO Antimicrob Agents Chemother. 1994 May;38(5):1190-3. Unique Identifier :
AIDSLINE MED/94346833
AB The pharmacodynamic relationship between a range of foscarnet exposure
measurements obtained from studying nine patients receiving ongoing
maintenance therapy for cytomegalovirus retinitis and a range of
efficacy values (days to retinitis progression) obtained by independent
examination of serial retinal photographs from the same nine patients
was analyzed. In the resulting proportional hazards models, the
foscarnet area under the concentration-time curve approached statistical
significance (P = 0.11) as a predictor of decreased risk of retinitis
progression.
DE Acquired Immunodeficiency Syndrome/COMPLICATIONS Adolescence Adult
Aged Chromatography, High Pressure Liquid Cytomegalovirus
Retinitis/*DRUG THERAPY/ETIOLOGY/MICROBIOLOGY Electrochemistry
Foscarnet/ADMINISTRATION & DOSAGE/*PHARMACOKINETICS/*THERAPEUTIC USE
Human Infusions, Intravenous Middle Age Support, Non-U.S. Gov't
Support, U.S. Gov't, P.H.S. Treatment Outcome CLINICAL TRIAL JOURNAL
ARTICLE RANDOMIZED CONTROLLED TRIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).